Therapeutic strategies for systemic necrotizing vasculitides

Allergology International

Volumn 56, Issue 2, 2007, Pages 105-111

  Guillevin, Loïc ^a   Pagnoux, Christian ^a  

^a Université Paris René Descartes ^*  (France)

Author keywords

ANCA; Immunosuppressants; Polyarteritis nodosa; Vasculitis; Wegener's granulomatosis

Indexed keywords

ABATACEPT; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIPARASITIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CD20 ANTIBODY; CORTICOSTEROID; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RIBAVIRIN; RITUXIMAB; VIDARABINE;

ANCA ASSOCIATED VASCULITIS; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG INDICATION; DRUG INHIBITION; HEALTH CARE ORGANIZATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MICROSCOPIC POLYANGIITIS; NECROTIZING ARTERITIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; REVIEW; SURVIVAL; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 34250881581     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.R-07-144     Document Type: Review

References (48)

1. Lightfoot RW Jr., Michel BA, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990;33: 1088-1093.
2. Masi AT, Hunder GG, Lie JT et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094-1100.
3. Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990;33: 1101-1107.
4. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187-192.
5. Kallenberg CG, Brouwer E, Weening JJ, Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int. 1994;46:1-15.
6. Guillevin L, Durand Gasselin B et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42:421-430.
7. Sinico RA, Di Toma L, Maggiore U et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52: 2926-2935.
8. Sable-Fourtassou R, Cohen P, Mahr A et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann. Intern. Med. 2005;143:632-638.
9. Guillevin L, Mahr A, Callard P et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005;84:313-322.
10. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26-37.
11. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 1992;116:488-498.
12. Gisselbrecht M, Cohen P, Lortholary O et al. HIV-related vasculitis: clinical presentation and therapeutic approach on six patients [letter]. Aids 1997;11:121-123.
13. Ferri C, Greco F, Longombardo G et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum. 1991;34:1606-1610.
14. Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette J. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2005;52:911- 915.
15. Garini G, Allegri L, Vaglio A, Buzio C. Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies. Ann. Ital. Med. Int. 2005;20:71-80.
16. Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101:3827-3834.
17. Gisselbrecht M, Cohen P, Lortholary O et al. Human immunodeficiency virus-related vasculitis. Clinical presentation of and therapeutic approach to eight cases. Ann. Med. Interne. (Paris) 1998;149:398-405.
18. Guillevin L, Lhote F, Gayraud M et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996;75:17-28.
19. Gayraud M, Guillevin L, le Toumelin P et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. French Vasculitis Study Group. Arthritis Rheum. 2001;44:666-675.
20. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Qjm 1994;87:671-678.
21. Ribi C, Cohen P, Pagnoux C et al. Treatment of Churg-Srauss syndrome without poor prognostic factors. A prospective randomized study in seventy two patients. In press 2007.
22. Frohnert P, Sheps S. Long term follow-up study of polyarteritis nodosa. Am. J. Med. 1967;43:8-14.
23. Guillevin L, Cohen P, Mahr A et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum. 2003;49:93-100.
24. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 2003;349:36-44.
25. De Groot K, Rasmussen N, Bacon PA et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461-2469.
26. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum. 2004;51:278-283.
27. Guillevin L, Cordier J, Lhote F et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 1997;40:2187-2198.
28. Adu D, Pall A, Luqmani RA et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Qjm 1997;90:401-409.
29. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J. Am. Soc. Nephrol. 1996;7:33-39.
30. Pusey C, Rees A, Evans D et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 1991;40:757-763.
31. Jayne D, Gaskin G, Rasmussen N et al. Randomised trial of plasma exchange versus methyl prednisolone for severe renal vasculitis. 2006.
32. Jayne DR, Chapel H, Adu D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Qjm 2000;93:433-439.
33. Jayne DR, Lockwood CM. Intravenous immunoglobulins as sole therapy for systemic vasculitis. Br. J. Rheumatol. 1996;35:1150-1153.
34. Levy Y, Uziel Y, Zandman GG et al. Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann. Rheum. Dis. 2003;62:1221-1223.
35. Richter C, Schnabel A, Csernok E, De Groot K, Reinhold KE, Gross WL. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin. Exp. Immunol. 1995;101:2-7.
36. Martinez V, Pagnoux C, Mahr A, Mouthon L, Guillevin L, et le Groupe Français d' Etudes des Vascularites. Intravenous immunoglobulins for relapses of ANCA-associated systemic vasculitides: final analysis of a prospective, open and multicenter trial. American College of Rheumatology, San Diego, poster 1752. Arthritis Rheum. 2006.
37. Bjoro K, Froland S, Yun Z, Samdal H, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N. Engl. J. Med. 1994;331:1607-1611.
38. Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 2001;62:133-137.
39. Jayne DR, Esnault VL, Lockwood CM. ANCA antiidiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J. Autoimmun. 1993;6:207-219.
40. Guilpain P, Chanseaud Y, Tamby MC et al. Pathogénie des vascularites systemiques primitives (I): Les vascularites ANCA positives. Presse. Med. 2005;34:1013-1022.
41. Bartolucci P, Ramanoelina J, Cohen P et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002;41:1126-1132.
42. Booth A, Harper L, Hammad T et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 2004;15:717-721.
43. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 2005;352: 351-361.
44. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. 2006;173: 180-187.
45. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J. Intern. Med. 2005;257:540-548.
46. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 2004;65: 1440-1448.
47. Steiner K, Moosig F, Csernok E et al. Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis. Clin. Exp. Immunol. 2001; 126:143-150.
48. Krumbholz M, Specks U, Wick M, Kalled SL, Jenne D, Meinl E. BAFF is elevated in serum of patients with Wegener's granulomatosis. J. Autoimmun. 2005;25:298-302.